Federal Register / Vol. 62, No. 202 / Monday, October 20, 1997 / Notices 54461

Barnett Community Development

Corporation, Jacksonville, Florida, and

thereby engage in investing in

corporations or projects designed

primarily to promote community

welfare, pursuant to § 225.28(b)(12) of

the Board’s Regulation Y; EquiCredit

Corporation, Jacksonville, Florida, and

its direct and indirect subsidiaries, and

thereby engage in the activities of

originating home equity and purchase

money loans, acquiring such loans

originated from third parties, and

securitizing such loans in the secondary

market, pursuant to § 225.28(b)(1) of the

Board’s Regulation Y, and in acting as

principal, agent, or broker for credit

related insurance, pursuant to §

225.28(b)(11) of the Board’s Regulation

Y; Equity/Protect Reinsurance

Company, Jacksonville, Florida, and

thereby engage in the activities of

reinsuring credit related insurance

policies sold to EquiCredit Corporation

customers, pursuant to § 225.28(b)(11)

of the Board’s Regulation Y; and Honor

Technologies, Inc., Maitland, Florida,

and thereby engage in operating an

electronic funds transfer network and in

data processing and management

consulting activities, pursuant to §§

225.28(b)(9) and (b)(14), respectively of

the Board’s Regulation Y.

Board of Governors of the Federal Reserve

System, October 14, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–27636 Filed 10–17–97; 8:45 am]

BILLING CODE 6210–01–F

GENERAL SERVICES

ADMINISTRATION

[GSA Bulletin FPMR D–245]

Public Buildings and Space

TO: Heads of Federal Agencies.

SUBJECT: Protecting Federal Employees

and the Public From Exposure to

Tobacco Smoke in the Federal

Workplace.

1. PURPOSE. This bulletin announces

the policy concerning the protection of

Federal employees and the public from

exposure to tobacco smoke in the

Federal workplace.

2. EXPIRATION DATE. This bulletin

contains information of a continuing

nature and will remain in effect until

canceled.

Background

a. On August 9, 1997, President

Clinton signed Executive Order 13058,

entitled ‘‘Protecting Federal Employees

and the Public From Exposure to

Tobacco Smoke in the Federal

Workplace,’’ (62 FR 43451, August 13,

1997), to establish a smoke-free

environment for Federal employees and

members of the public visiting or using

Federal facilities. The General Services

Administration (GSA) is providing

governmentwide policy guidance

concerning the requirements of this

Executive Order so that federal agencies

may benefit from GSA’s real property

management expertise.

b. The policy previous to Executive

Order 13058, enunciated in FPMR

§ 101–20.105–3, declared all GSAcontrolled space non-smoking except

where designated smoking areas are

identified by agency heads. This

Executive Order prohibits, with some

exceptions, the smoking of tobacco

products in all interior space owned,

rented or leased by the executive branch

of the Federal Government. GSA will

amend FPMR § 101–20.105–3 in the

near future to reflect the new policy in

this Executive Order.

c. Unlike the previous policy, this

Executive Order requires that

designated smoking areas be enclosed

and exhausted directly to the outside

and away from air intake ducts, and

maintained under negative pressure

sufficient to contain tobacco smoke

within the designated area. Agency

officials must not require workers to

enter such areas during business hours

while smoking is ongoing.

Action

a. In accordance with Executive Order

13058, Federal agencies must prohibit

the smoking of tobacco products in all

interior space owned, rented, or leased

by the executive branch of the Federal

Government, and in any outdoor areas

under executive branch control in front

of air intake ducts.

b. The only exceptions are designated

smoking areas; residential

accommodations for persons voluntarily

or involuntarily residing, on a

temporary or long-term basis, in a

building owned, leased, or rented by the

Federal Government; portions of

federally-owned buildings leased,

rented, or otherwise provided (in their

entirety) to nonfederal parties; and

places of employment in the private

sector or in other nonfederal

governmental units that serve as the

permanent or intermittent duty station

of one or more federal employees.

c. The heads of Federal agencies may

establish limited and narrow exceptions

that are necessary to accomplish agency

missions. Such exception must be in

writing, approved by the agency head,

and to the fullest extent possible

provide protection of nonsmokers from

exposure to environmental tobacco

smoke. Authority to establish such

exceptions may not be delegated.

d. The heads of Federal agencies must

evaluate the need to restrict smoking at

doorways and in courtyards under

executive branch control in order to

protect workers and visitors from

environmental tobacco smoke, and may

restrict smoking in these areas in light

of this evaluation.

e. The heads of Federal agencies are

encouraged to use existing authority to

establish programs designed to help

employees stop smoking.

f. The heads of Federal agencies must

implement and ensure compliance with

the policy set forth in this Executive

Order no later than August 9, 1998.

Prior to this date, the heads of Federal

agencies must inform all employees and

visitors to executive branch facilities

about the requirements of this order,

inform their employees of the health

risks of exposure to environmental

tobacco smoke, and undertake related

activities as necessary.

Dated: October 9, 1997.

G. Martin Wagner,

Associate Administrator, Office of

Governmentwide Policy.

[FR Doc. 97–27703 Filed 10–17–97; 8:45 am]

BILLING CODE 6820–23–P

GENERAL SERVICES

ADMINISTRATION

Office of Transportation Audits;

Stocking Change of a Standard Form

AGENCY: General Services

Administration.

ACTION: Notice.

SUMMARY: The General Services

Administration/Office of Transportation

is changing the stocking of the following

Standard form because of low use

demand:

SF 362, U.S. Government Freight Loss/

Damage Claim

Since this form is not authorized for

local reproduction, you can obtain the

updated camera copy in three ways:

From the ‘‘U.S. Government

Management Policy CD–ROM’’;

On the internet. Address: http://

www.gsa.gov/forms; or

From CARM, Attn.: Barbara Williams,

(202) 501–0581.

FOR FURTHER INFORMATION CONTACT:

Transportation Audit Division, (202)

219–1494. This contact is for

information on completing the form and

interpreting the FPMR only.

DATES: Effective October 20, 1997.
54462 Federal Register / Vol. 62, No. 202 / Monday, October 20, 1997 / Notices

Dated: October 1, 1997.

Barbara M. Williams,

Deputy Standard and Optional Forms

Management Officer.

[FR Doc. 97–27648 Filed 10–17–97; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 94N–0227]

Nandlal G. Rana; Debarment Order

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is issuing an

order under the Federal Food, Drug, and

Cosmetic Act (the act) permanently

debarring Mr. Nandlal G. Rana, 184

Parsonage Rd., Edison, NJ 08817, from

providing services in any capacity to a

person that has an approved or pending

drug product application. FDA bases

this order on a finding that Mr. Rana

was convicted of a felony under Federal

law for conduct relating to the

regulation of a drug product under the

act. Mr. Rana failed to request a hearing

and, therefore, has waived his

opportunity for a hearing concerning

this action.

EFFECTIVE DATE: October 20, 1997.

ADDRESSES: Application for termination

of debarment to the Dockets

Management Branch (HFA–305), Food

and Drug Administration, 12420

Parklawn Dr., rm. 1–23, Rockville, MD

20857.

FOR FURTHER INFORMATION CONTACT:

Christine F. Rogers, Center for Drug

Evaluation and Research (HFD–7), Food

and Drug Administration, 5600 Fishers

Lane, Rockville, MD 20857, 301–594–

2041.

SUPPLEMENTARY INFORMATION:

I. Background

On October 5, 1993, the United States

District Court for the District of

Maryland entered judgment against Mr.

Nandlal G. Rana for one count of

obstructing an agency proceeding, a

Federal felony under 18 U.S.C. 1505.

As a result of this conviction, FDA

served Mr. Rana by certified mail on

February 17, 1995, a notice proposing to

permanently debar him from providing

services in any capacity to a person that

has an approved or pending drug

product application, and offered him an

opportunity for a hearing on the

proposal. The proposal was based on a

finding, under section 306(a)(2)(B) of

the act (21 U.S.C. 335a(a)(2)(B)), that Mr.

Rana was convicted of a felony under

Federal law for conduct relating to the

regulation of a drug product. Mr. Rana

was provided 30 days to file objections

and request a hearing. Mr. Rana did not

request a hearing. His failure to request

a hearing constitutes a waiver of his

opportunity for a hearing and a waiver

of any contentions concerning his

debarment.

II. Findings and Order

Therefore, the Director, Center for

Drug Evaluation and Research, under

section 306(a)(2)(B) of the act, and

under authority delegated to her (21

CFR 5.99), finds that Mr. Nandlal G.

Rana has been convicted of a felony

under Federal law for conduct relating

to the regulation of a drug product.

As a result of the foregoing finding,

Mr. Nandlal G. Rana is permanently

debarred from providing services in any

capacity to a person with an approved

or pending drug product application

under section 505, 507, 512, or 802 of

the act (21 U.S.C. 355, 357, 360b, or

382), or under section 351 of the Public

Health Service Act (42 U.S.C. 262),

effective October 20, 1997 (sections

306(c)(1)(B) and (c)(2)(A)(ii) and 201(dd)

of the act (21 U.S.C. 321(dd))). Any

person with an approved or pending

drug product application who

knowingly uses the services of Mr.

Rana, in any capacity, during his period

of debarment, will be subject to civil

money penalties (section 307(a)(6) of the

act (21 U.S.C. 335b(a)(6))). If Mr. Rana,

during his period of debarment,

provides services in any capacity to a

person with an approved or pending

drug product application, he will be

subject to civil money penalties (section

307(a)(7) of the act). In addition, FDA

will not accept or review any

abbreviated new drug applications

submitted by or with the assistance of

Mr. Rana during his period of

debarment.

Any application by Mr. Rana for

termination of debarment under section

306(d)(4) of the act should be identified

with Docket No. 94N–0227 and sent to

the Dockets Management Branch

(address above). All such submissions

are to be filed in four copies. The public

availability of information in these

submissions is governed by 21 CFR

10.20(j). Publicly available submissions

may be seen in the Dockets Management

Branch between 9 a.m. and 4 p.m.,

Monday through Friday.

Dated: October 1, 1997.

Janet Woodcock,

Director, Center for Drug Evaluation and

Research.

[FR Doc. 97–27693 Filed 10–17–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committee Meeting;

Amendment of Notice

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing an

amendment to the notice of meeting of

the Cardiovascular and Renal Drugs

Advisory Committee. This meeting was

announced in the Federal Register of

September 18, 1997. The amendment is

being made to: Remove the second

agenda item scheduled on October 23,

1997; add a closed session to the agenda

scheduled on October 23, 1997; and

provide a new location site for this

closed session. There are no other

changes. This amendment will be

announced at the beginning of the open

portion of the meeting.

FOR FURTHER INFORMATION CONTACT: Joan

C. Standaert, Center for Drug Evaluation

and Research (HFD–110), 419–259–

6211, or Danyiel D’Antonio (HFD–21),

301–443–5455, Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, or FDA Advisory

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), code 12533.

Please call the Information Line for upto-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the

Federal Register of September 18, 1997

(62 FR 49015), FDA announced that a

meeting of the Cardiovascular and Renal

Drugs Advisory Committee would be

held on October 23 and 24, 1997. This

amendment is to provide an update to

the information provided earlier

pertaining to the October 23, 1997,

meeting day. There are no changes for

the October 24, 1997, meeting day. On

page 49015, beginning in column 3,

portions of the notice pertaining to the

October 23, 1997, meeting day are

amended to read as follows:

Location: October 23, 1997, 8:30 a.m.

to 2 p.m., National Institutes of Health,

Clinical Center, Bldg. 10, Jack Masur

Auditorium, 9000 Rockville Pike,

Bethesda, MD.